Alogliptin Tablet, Film Coated
Product Images NDC 50090-5574

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Alogliptin (NDC 50090-5574). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Alogliptin 01)

Chemical structure diagram of Alogliptin, showing its molecular components including aromatic rings, nitrogen, oxygen, and a cyanide group, depicted with stereochemistry annotations (Z and R) and a phenylacetic acid component.*

FDA Label Image

Figure 1 (Alogliptin 02)

A chart displaying the pharmacokinetic interaction of Alogliptin with various coadministered drugs, showing ratios and 90% confidence intervals for AUC and Cmax. It includes substrates and coadministered drugs grouped by enzyme systems (e.g., CYP1A2, CYP2C8) alongside recommendations indicating no dose adjustment is needed.*

FDA Label Image

Figure 2 (Alogliptin 03)

A chart showing the pharmacokinetic (PK) interaction ratios and 90% confidence intervals for Alogliptin when coadministered with various drugs. It compares the area under the curve (AUC) and maximum concentration (Cmax) ratios of Alogliptin alone versus with other drugs including metformin, cimetidine, gemfibrozil, pioglitazone, fluconazole, ketoconazole, atorvastatin, cyclosporine, and digoxin. The recommendation column notes no dose adjustment is necessary for any of the drug combinations shown.*

FDA Label Image

Figure 3 (Alogliptin 04)

A bar chart depicting least squares mean change in A1C (%) for different treatment groups at baseline mean A1C 8.5 and 8.6. It compares placebo, Alogliptin 25 mg, Pioglitazone doses (15 mg, 30 mg, 45 mg), and combinations of Alogliptin 25 mg with Pioglitazone (15 mg, 30 mg, 45 mg). The chart shows the change in A1C levels, with combination treatments generally showing greater reductions with statistical significance noted (p ≤ 0.001) compared to monotherapies.*

FDA Label Image

Figure 4 (Alogliptin 05)

Kaplan-Meier cumulative event probability curve comparing Placebo (P) and NESINA (N) over 30 months from randomization. The chart shows event probabilities on the y-axis and months on the x-axis, with sample sizes at risk noted below the timeline. A hazard ratio (HR) with 98% confidence interval is provided, comparing NESINA to Placebo.*

FDA Label Image

Label Image (Lbl500905574)

Label for Alogliptin 25 mg film-coated tablets by A-S Medication Solutions. The label indicates the active ingredient as 34 mg alogliptin benzoate equivalent to 25 mg alogliptin. The package contains 30 tablets. Storage instructions specify to store at 77 degrees Fahrenheit.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.